<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The search for molecular biomarkers for diagnosing and classifying <z:hpo ids='HP_0000726'>dementias</z:hpo> is becoming a high priority need </plain></SENT>
<SENT sid="1" pm="."><plain>Neurosin (Kallikrein 6, hk6) is one molecule with promising preliminary results since its levels in brain tissue, cerebrospinal fluid and blood have been found to be abnormal in <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD) </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we measured plasmatic levels of neurosin in healthy individuals and patients with cognitive symptoms independently of what the final diagnosis was </plain></SENT>
<SENT sid="3" pm="."><plain>We collected plasma samples from 228 controls and 447 patients finally diagnosed with either AD, Mild <z:hpo ids='HP_0100543'>Cognitive Impairment</z:hpo>, <z:hpo ids='HP_0000726'>Dementia</z:hpo> with <z:hpo ids='HP_0100315'>Lewy Bodies</z:hpo> or Parkinson-<z:hpo ids='HP_0000726'>Dementia</z:hpo>, <z:hpo ids='HP_0002145'>Frontotemporal Dementia</z:hpo>, <z:e sem="disease" ids="C0020179" disease_type="Disease or Syndrome" abbrv="HD">Huntington's disease</z:e>, Primary Progressive <z:hpo ids='HP_0002381'>Aphasia</z:hpo>, <z:e sem="disease" ids="C0393570" disease_type="Disease or Syndrome" abbrv="">Corticobasal degeneration</z:e>, <z:e sem="disease" ids="C0022336" disease_type="Disease or Syndrome" abbrv="">Creutzfeldt-Jakob's disease</z:e> or <z:e sem="disease" ids="C0033797" disease_type="Mental or Behavioral Dysfunction" abbrv="">Pseudodementia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>We found that plasmatic levels of neurosin increase with age in healthy individuals and decrease in patients with AD </plain></SENT>
<SENT sid="5" pm="."><plain>Plasmatic levels of neurosin differ significantly between AD and Vascular <z:hpo ids='HP_0000726'>Dementia</z:hpo>, <z:e sem="disease" ids="C0033797" disease_type="Mental or Behavioral Dysfunction" abbrv="">Pseudodementia</z:e> and the control group </plain></SENT>
<SENT sid="6" pm="."><plain>Analyses comparing any other form of neurodegenerative <z:hpo ids='HP_0000726'>dementia</z:hpo> to the AD group did not show significant differences </plain></SENT>
<SENT sid="7" pm="."><plain>In conclusion, measurement of plasmatic levels of neurosin is useful to distinguish AD patients from subjects without neurodegenerative <z:hpo ids='HP_0000726'>dementia</z:hpo> (either <z:e sem="disease" ids="C0033797" disease_type="Mental or Behavioral Dysfunction" abbrv="">Pseudodementia</z:e>, Vascular <z:hpo ids='HP_0000726'>Dementia</z:hpo> or controls) although it is not useful to distinguish among neurodegenerative <z:hpo ids='HP_0000726'>dementias</z:hpo> </plain></SENT>
</text></document>